UBS AM
PRLD icon

UBS AM’s Prelude Therapeutics PRLD Stock Holding History

UBS AM’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,273,894
Closed -$13M – 2666
2023
Q2 		$13M Hold
2,273,894
– – 0.01% 875
2023
Q1 		$13M Sell
2,273,894
-62,050
-3% -$378K 0.01% 875
2022
Q4 		$14.1M Sell
2,335,944
-66,651
-3% -$427K 0.01% 834
2022
Q3 		$15.9M Sell
2,402,595
-17,932
-0.7% -$121K 0.01% 825
2022
Q2 		$12.6M Sell
2,420,527
-1,800
-0.1% -$9.16K 0.01% 876
2022
Q1 		$16.7M Buy
2,422,327
+908,641
+60% +$8.31M 0.01% 892
2021
Q4 		$18.8M Buy
1,513,686
+30,367
+2% +$494K 0.01% 912
2021
Q3 		$46.4M Buy
1,483,319
+195,584
+15% +$6.33M 0.02% 640
2021
Q2 		$36.9M Buy
1,287,735
+644,756
+100% +$23M 0.02% 709
2021
Q1 		$27.9M Buy
642,979
+126,950
+25% +$8.42M 0.01% 783
2020
Q4 		$36.9M Sell
516,029
-210,434
-29% -$10.5M 0.02% 687
2020
Q3 		$21.9M Buy
+726,463
New +$20.5M 0.01% 740

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

UBS AM's PRLD Position: Q3 2023 in Review

UBS AM sold out of Prelude Therapeutics (PRLD) in Q3 2023, closing a stake of 2,273,894 shares — an estimated $13M sold.

UBS AM first reported a position in PRLD in Q3 2020 and held it in 12 quarters. The position peaked at $46.4M in Q3 2021. 60 funds tracked by Wall St. Rank hold PRLD as of Q3 2023.

  • UBS AM reported no remaining Prelude Therapeutics position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 2,273,894 Prelude Therapeutics shares in Q3 2023, an estimated $13M.
  • UBS AM first reported a position in Prelude Therapeutics in Q3 2020 and held it in 12 quarters.
  • UBS AM's Prelude Therapeutics position peaked at $46.4M in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.